120
Participants
Start Date
August 31, 2014
Primary Completion Date
August 31, 2018
Study Completion Date
February 28, 2019
Icotinib with concurrent radiotherapy
Icotinib: 125 mg is administered orally three times per day.
Chemoradiotherapy
Etoposide 50mg/m2, ivgtt, d1-d5; cisplatin 50mg/m2, ivgtt, d1 and d8, every 28 days for a cycle, a total of 2 cycles
Chinese Academy of Medical Sciences Cancer Hospital, Beijing
People's Liberation Army 307 Hospital, Beijing
Peking University Third Hospital, Beijing
Beijing Union Medical College Hospital, Beijing
Liaoning Provincial Tumor Hospital, Shenyang
Tumor Hospital of Jilin Province, Changchun
Cancer Hospital of Harbin Medical University, Harbin
Shanghai Chest Hospital, Shanghai
Fudan University Cancer Hospital, Shanghai
Jiangsu Cancer Hospital, Nanjing
Nantong Tumor Hospital, Nantong
Tianjin Cancer Hospital, Tianjin
Hangzhou First People's Hospital, Hangzhou
Zhejiang Cancer Hospital, Hangzhou
Jiangxi Provincial Cancer Hospital, Nanchang
Hunan Provincial Tumor Hospital, Changsha
Tongji Hospital, Wuhan
First Affiliated Hospital of Zhengzhou University, Zhengzhou
Sun Yat-sen Cancer Hospital, Guangzhou
Nanfang Hospital, Guangzhou
Dongguan City People's Hospital, Dongguan
Guangxi Zhuang Autonomous Region People's Hospital, Nanning
Sichuan Provincial Tumor Hospital, Chengdu
Tumor Hospital of Yunnan Province, Kunming
First Affiliated Hospital of Xinjiang Medical University, Ürümqi
Shanxi Tumor Hospital, Taiyuan
Lead Sponsor
Betta Pharmaceuticals Co., Ltd.
INDUSTRY